Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Core Insights - Eledon Pharmaceuticals presented updated data on tegoprubart, an anti-CD40L antibody, at the American Transplant Congress, indicating its potential for preventing organ rejection in kidney transplant patients [1][2] - The ongoing Phase 1b trial shows promising results, with an overall mean estimated glomerular filtration rate (eGFR) of 70.5 mL/min/1.73m² after day 30 post-transplant, significantly higher than the typical 50 mL/min/1.73m² reported with standard calcineurin inhibitor therapies [2][3] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with tegoprubart as its lead investigational product [5] - The company is conducting multiple clinical trials, including a Phase 1b trial, a Phase 2 trial (BESTOW), and a long-term safety and efficacy extension study [4] Clinical Trial Results - Data from 13 participants in the Phase 1b trial indicate that tegoprubart is generally safe and well tolerated, with no cases of hyperglycemia, new onset diabetes, or tremor reported [3] - Two participants who completed 12 months on therapy post-transplant demonstrated mean eGFRs above 90 mL/min/1.73m², further supporting the drug's efficacy [2] Future Plans - The company aims to continue accruing data from the ongoing Phase 1b and open-label extension studies while also enrolling participants in the Phase 2 BESTOW trial, with completion expected by the end of the year [2]